A detailed history of Janney Montgomery Scott LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Janney Montgomery Scott LLC holds 58,817 shares of EXEL stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58,817
Previous 60,746 3.18%
Holding current value
$1.55 Million
Previous $1.44 Million 8.32%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$20.34 - $23.73 $39,235 - $45,775
-1,929 Reduced 3.18%
58,817 $1.32 Million
Q1 2024

May 01, 2024

BUY
$20.17 - $23.93 $70,796 - $83,994
3,510 Added 6.13%
60,746 $1.44 Million
Q4 2023

Feb 07, 2024

SELL
$19.25 - $24.13 $22,907 - $28,714
-1,190 Reduced 2.04%
57,236 $1.37 Million
Q3 2023

Nov 08, 2023

SELL
$19.04 - $22.74 $110,793 - $132,324
-5,819 Reduced 9.06%
58,426 $1.28 Million
Q2 2023

Jul 26, 2023

BUY
$18.17 - $20.48 $49,731 - $56,053
2,737 Added 4.45%
64,245 $1.23 Million
Q1 2023

Apr 28, 2023

BUY
$16.3 - $19.41 $63,570 - $75,699
3,900 Added 6.77%
61,508 $1.19 Million
Q4 2022

Feb 01, 2023

BUY
$14.96 - $17.39 $102,595 - $119,260
6,858 Added 13.51%
57,608 $924,000
Q3 2022

Oct 25, 2022

SELL
$15.68 - $22.27 $63,676 - $90,438
-4,061 Reduced 7.41%
50,750 $796,000
Q2 2022

Aug 03, 2022

SELL
$17.44 - $23.16 $86,345 - $114,665
-4,951 Reduced 8.28%
54,811 $1.15 Million
Q1 2022

May 04, 2022

BUY
$17.03 - $22.67 $20,895 - $27,816
1,227 Added 2.1%
59,762 $1.36 Million
Q4 2021

Jan 27, 2022

SELL
$15.84 - $21.88 $162,280 - $224,160
-10,245 Reduced 14.9%
58,535 $1.07 Million
Q3 2021

Oct 29, 2021

BUY
$16.3 - $21.14 $312,259 - $404,978
19,157 Added 38.61%
68,780 $1.45 Million
Q2 2021

Jul 26, 2021

BUY
$17.95 - $25.56 $13,803 - $19,655
769 Added 1.57%
49,623 $904,000
Q1 2021

Apr 27, 2021

BUY
$20.53 - $25.22 $1 Million - $1.23 Million
48,854 New
48,854 $1.1 Million
Q4 2018

Feb 01, 2019

SELL
$13.65 - $21.8 $199,904 - $319,261
-14,645 Closed
0 $0
Q3 2018

Nov 05, 2018

SELL
$15.87 - $22.4 $40,865 - $57,679
-2,575 Reduced 14.95%
14,645 $260,000
Q2 2018

Jul 24, 2018

BUY
$18.56 - $22.45 $76,003 - $91,932
4,095 Added 31.2%
17,220 $371,000
Q1 2018

Apr 19, 2018

BUY
$22.15 - $31.89 $3,765 - $5,421
170 Added 1.31%
13,125 $291,000
Q4 2017

Feb 14, 2018

BUY
$24.23 - $30.93 $313,899 - $400,698
12,955
12,955 $394,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Janney Montgomery Scott LLC Portfolio

Follow Janney Montgomery Scott LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janney Montgomery Scott LLC, based on Form 13F filings with the SEC.

News

Stay updated on Janney Montgomery Scott LLC with notifications on news.